ACET insider transaction filings
Adicet Bio, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-07. Screen ACET transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 1 Form 4 filing. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 1.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Klickstein Lloyd — Chief Medical Officer, Director | 1 | — | — | 1 |
Recent Form 4 filings — Adicet Bio, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-07 | 4 | Klickstein Lloyd — Chief Medical Officer, Director | Grant/award (A): 18,300 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Peng Katie — Director | Grant/award (A): 4,200 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Aftab Blake — Chief Scientific Officer | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Klickstein Lloyd — Director | Grant/award (A): 4,200 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Sinclair Andrew — Director | Grant/award (A): 4,200 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Grissinger Michael — Director | Grant/award (A): 4,200 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Chodakewitz Jeffrey — Director | Grant/award (A): 4,200 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Schor Chen — President & CEO, Director | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | DUBIN STEVE — Director | Grant/award (A): 4,200 (derivative) @ $0 | EDGAR |
| 2026-04-29 | 4 | RA CAPITAL MANAGEMENT, L.P. — 10% owner RA Capital Healthcare Fund LP — 10% owner Kolchinsky Peter — 10% owner Shah Rajeev M. — 10% owner | Other (J): 250,000 · Other (J): 250,000 (derivative) | EDGAR |
| 2026-04-13 | 4 | RA CAPITAL MANAGEMENT, L.P. — 10% owner RA Capital Healthcare Fund LP — 10% owner Kolchinsky Peter — 10% owner Shah Rajeev M. — 10% owner | Purchase (P): 74,577 @ $7.04 · Purchase (P): 74,268 @ $7.21 · Purchase (P): 74,751 @ $7.27 | EDGAR |
| 2026-04-09 | 4 | ORBIMED ADVISORS LLC — 10% owner OrbiMed Capital GP V LLC — 10% owner OrbiMed Capital GP VI LLC — 10% owner OrbiMed Genesis GP LLC — 10% owner OrbiMed Advisors Israel II Ltd — 10% owner OrbiMed Israel GP II, L.P. — 10% owner OrbiMed Israel GP Ltd. — 10% owner OrbiMed Israel BioFund GP Limited Partnership — 10% owner | Sale (S): 29,319 @ $6.53 · Sale (S): 2,400 @ $6.38 · Sale (S): 32,523 @ $6.29 · Sale (S): 40,416 @ $6.52 | EDGAR |
| 2026-03-27 | 4 | Maltzman Julia D. — Chief Medical Officer | Grant/award (A): 72,555 (derivative) @ $0 | EDGAR |
| 2026-03-27 | 4 | Aftab Blake — Chief Scientific Officer | Grant/award (A): 72,555 (derivative) @ $0 | EDGAR |
| 2026-03-27 | 4 | Healey Don — Chief Technology Officer | Grant/award (A): 43,361 (derivative) @ $0 | EDGAR |
| 2026-03-27 | 4 | Harvey Brian Nicholas — Chief Financial Officer | Grant/award (A): 43,361 (derivative) @ $0 | EDGAR |
| 2026-03-27 | 4 | Schor Chen — President & CEO, Director | Grant/award (A): 468,555 (derivative) @ $0 | EDGAR |
| 2026-01-27 | 4 | Aftab Blake — Chief Scientific Officer | Tax withholding (F): 535 @ $8.44 | EDGAR |
| 2026-01-27 | 4 | Healey Don — Chief Technology Officer | Tax withholding (F): 535 @ $8.44 | EDGAR |
| 2026-01-27 | 4 | Harvey Brian Nicholas — Chief Financial Officer | Tax withholding (F): 546 @ $8.44 | EDGAR |
| 2026-01-27 | 4 | Schor Chen — President & CEO, Director | Tax withholding (F): 1,755 @ $8.44 | EDGAR |
| 2025-10-10 | 4 | ORBIMED ADVISORS LLC — 10% owner OrbiMed Capital GP V LLC — 10% owner OrbiMed Capital GP VI LLC — 10% owner OrbiMed Genesis GP LLC — 10% owner OrbiMed Advisors Israel II Ltd — 10% owner OrbiMed Israel GP II, L.P. — 10% owner OrbiMed Israel GP Ltd. — 10% owner OrbiMed Israel BioFund GP Limited Partnership — 10% owner | Purchase (P): 1,500,000 @ $1 · Purchase (P): 3,500,000 @ $1 | EDGAR |
| 2025-06-13 | 4 | Klickstein Lloyd — Director | Grant/award (A): 5,900 @ $0 · Grant/award (A): 26,400 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Peng Katie — Director | Grant/award (A): 5,900 @ $0 · Grant/award (A): 26,400 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Sinclair Andrew — Director | Grant/award (A): 5,900 @ $0 · Grant/award (A): 26,400 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Chodakewitz Jeffrey — Director | Grant/award (A): 5,900 @ $0 · Grant/award (A): 26,400 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | DUBIN STEVE — Director | Grant/award (A): 5,900 @ $0 · Grant/award (A): 26,400 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4 | Grissinger Michael — Director | Grant/award (A): 70,200 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Aftab Blake — Chief Scientific Officer | Grant/award (A): 275,000 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Maltzman Julia D. — Chief Medical Officer | Grant/award (A): 750,000 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Healey Don — Chief Technology Officer | Grant/award (A): 275,000 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Harvey Brian Nicholas — Chief Financial Officer | Grant/award (A): 324,040 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Schor Chen — President & CEO, Director | Grant/award (A): 763,829 (derivative) @ $0 | EDGAR |
| 2025-01-28 | 4 | Aftab Blake — Chief Scientific Officer | Tax withholding (F): 6,270 @ $0.92 | EDGAR |
| 2025-01-28 | 4 | Healey Don — Chief Technology Officer | Tax withholding (F): 8,560 @ $0.92 | EDGAR |
| 2025-01-28 | 4 | Harvey Brian Nicholas — Chief Financial Officer | Tax withholding (F): 8,752 @ $0.92 | EDGAR |
| 2025-01-28 | 4 | Schor Chen — President & CEO, Director | Tax withholding (F): 28,101 @ $0.92 | EDGAR |
| 2024-08-23 | 4 | Sinclair Andrew — Director | Disposition to issuer (D): 28,828 (derivative) @ $0 · Grant/award (A): 28,828 (derivative) @ $0 · Disposition to issuer (D): 18,500 (derivative) @ $0 · Grant/award (A): 18,500 (derivative) @ $0 · Disposition to issuer (D): 8,172 (derivative) @ $0 · Grant/award (A): 8,172 (derivative) @ $0 · +4 more | EDGAR |
| 2024-08-23 | 4 | Peng Katie — Director | Disposition to issuer (D): 70,200 (derivative) @ $0 · Grant/award (A): 70,200 (derivative) @ $0 | EDGAR |
| 2024-08-23 | 4 | Jakobovits Aya — Director | Disposition to issuer (D): 30,000 (derivative) @ $0 · Grant/award (A): 30,000 (derivative) @ $0 · Disposition to issuer (D): 18,500 (derivative) @ $0 · Grant/award (A): 18,500 (derivative) @ $0 · Disposition to issuer (D): 18,500 (derivative) @ $0 · Grant/award (A): 18,500 (derivative) @ $0 · +2 more | EDGAR |
| 2024-08-23 | 4 | Chodakewitz Jeffrey — Director | Disposition to issuer (D): 30,000 (derivative) @ $0 · Grant/award (A): 30,000 (derivative) @ $0 · Disposition to issuer (D): 18,500 (derivative) @ $0 · Grant/award (A): 18,500 (derivative) @ $0 · Disposition to issuer (D): 18,500 (derivative) @ $0 · Grant/award (A): 18,500 (derivative) @ $0 · +2 more | EDGAR |
| 2024-08-23 | 4 | Kauffman Michael — Director | Disposition to issuer (D): 37,000 (derivative) @ $0 · Grant/award (A): 37,000 (derivative) @ $0 · Disposition to issuer (D): 18,500 (derivative) @ $0 · Grant/award (A): 18,500 (derivative) @ $0 · Disposition to issuer (D): 26,400 (derivative) @ $0 · Grant/award (A): 26,400 (derivative) @ $0 | EDGAR |
| 2024-08-23 | 4 | GORDON CARL L — Director, 10% owner | Disposition to issuer (D): 30,000 (derivative) @ $0 · Grant/award (A): 30,000 (derivative) @ $0 · Disposition to issuer (D): 18,500 (derivative) @ $0 · Grant/award (A): 18,500 (derivative) @ $0 · Disposition to issuer (D): 18,500 (derivative) @ $0 · Grant/award (A): 18,500 (derivative) @ $0 · +2 more | EDGAR |
| 2024-08-23 | 4 | DUBIN STEVE — Director | Disposition to issuer (D): 30,000 (derivative) @ $0 · Grant/award (A): 30,000 (derivative) @ $0 · Disposition to issuer (D): 18,500 (derivative) @ $0 · Grant/award (A): 18,500 (derivative) @ $0 · Disposition to issuer (D): 18,500 (derivative) @ $0 · Grant/award (A): 18,500 (derivative) @ $0 · +2 more | EDGAR |
| 2024-08-20 | 4 | Klickstein Lloyd — Director | Grant/award (A): 70,200 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Harvey Brian Nicholas — Chief Financial Officer | Grant/award (A): 374,829 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Kauffman Michael — Director | Grant/award (A): 5,900 @ $0 · Sale (S): 5,900 @ $1.43 · Grant/award (A): 26,400 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Schor Chen — President & CEO, Director | Grant/award (A): 1,770,427 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | GORDON CARL L — Director, 10% owner | Grant/award (A): 5,900 @ $0 · Grant/award (A): 26,400 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | DUBIN STEVE — Director | Grant/award (A): 5,900 @ $0 · Grant/award (A): 26,400 (derivative) @ $0 | EDGAR |
Recent 8-K events — Adicet Bio, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-08 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-01 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-18 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-28 | 8-K | 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-07 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-29 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-19 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ACET returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →